Perilymphatic Fistula Workup

  • Author: Peter S Roland, MD; Chief Editor: Arlen D Meyers, MD, MBA   more...
 
Updated: Apr 26, 2010
 

Laboratory Studies

  • No laboratory studies are relevant to the diagnosis of perilymphatic fistula (PLF). A possible future role for beta2-transferrin assay is discussed in Intraoperative details.
Next

Imaging Studies

  • Obtain gadolinium-enhanced MRI scans in all individuals with unilateral otologic symptoms to exclude acoustic neuroma or other structural lesions of the cerebellar pontine angle or neuraxis.
  • The incidence of perilymphatic fistula (PLF) is much higher in individuals with congenital deformities of the otic capsule. Consequently, a nonenhanced fine-cut CT scan of the temporal bones can be helpful, especially in children. A child with progressive or sudden neurosensory hearing loss in an ear that is incompletely developed has a much higher risk of perilymphatic fistula (PLF) than a child with normal inner ear radiographic morphology.
Previous
Next

Other Tests

Audiography

Obtain an audiogram in all patients with otologic symptomatology. Neurosensory hearing loss is a regular feature of perilymphatic fistula (PLF), but any pattern of neurosensory hearing loss can result from perilymphatic fistula (PLF). Because it is otherwise relatively uncommon, low-frequency hearing loss is perhaps a bit more suggestive of perilymphatic fistula (PLF); however, midfrequency, high-frequency, and flat losses are also consistent with the diagnosis. Fluctuating hearing loss is common with perilymphatic fistula (PLF), as it is with Ménière disease.

Some authors have reported a conductive loss in patients with perilymphatic fistula (PLF), but this probably represents a small percentage of patients.

Electrocochleography

ECoG is a method of measuring intracochlear electrical potential changes associated with hearing. Three separate responses can be obtained, as follows:

  • The cochlear microphonic is a stimulus-related alternating current (AC) potential that closely mimics the stimulus and therefore is difficult to separate from stimulus artifact. The technique used to produce standard electrocochleographic tracings eliminates the cochlear microphonic from the ECoG tracing.
  • The summating potential (SP) is a stimulus-related direct current (DC) potential that reflects the time-related displacement of the cochlear partition. The SP has been shown to be sensitive to inner ear fluid imbalance, particularly in Ménière disease and perilymphatic fistula (PLF).
  • The action potential is an AC potential that represents the compound action potential of the fiber's eighth nerve that discharges synchronously in response to a stimulus. The initial portion of the action potential also is known as wave I of the ABR.

The 2 methods of recording ECoG are transtympanic and extratympanic.

  • Transtympanic: A needle electrode passed through the tympanic membrane that rests on the promontory provides the largest and most easily readable tracings because it is a near-field potential. Fewer signals need to be averaged to obtain an interpretable response, and the potentials are much longer than in other methods of ECoG. Acceptance of transtympanic ECoG has been limited because it can be painful and because a physician's presence is required to pass the electrode through the tympanic membrane.
  • Extratympanic: Extratympanic ECoG is comfortable and noninvasive, and it can be performed in a nonmedical setting. However, the size of the reported potentials is significantly smaller than with transtympanic ECoG, and, consequently, the reported potentials are more difficult to identify and interpret.

ECoG is useful in the diagnosis of both Ménière disease and PLF. Both conditions produce an elevated SP/AP ratio. Increase in the SP/AP ratio appears to result because of enlargement of the SP component in patients with Ménière disease. The mechanism by which it increases in perilymphatic fistula (PLF) is controversial. Some authors believe that the increase in SP/AP ratio in patients with perilymphatic fistula (PLF) may be the consequence of a decrease in the AP.

Several guinea pig studies have shown consistent increases in the SP/AP ratio in guinea pigs with artificially induced perilymphatic fistulas (PLFs). Gibson has demonstrated an increase in the SP/AP ratio during stapedectomy.[14] The creation of a control hole in the footplate is not sufficient to produce a change in the SP/AP ratio; a change is noted only after some perilymph has been removed from the vestibule. Meyerhoff and Yellin have demonstrated that in individuals with surgically proven perilymphatic fistulas (PLFs) who have elevated SP/AP ratios preoperatively, the SP/AP ratio reliably returns to normal after surgical repair of the fistula.[15]

Fistula test

Fistula testing has been shown to yield positive results in patients with perilymphatic fistula (PLF). The application of positive pressure to a tympanic membrane in an ear with a fistula is known to possibly produce nystagmus. The production of nystagmus secondary to positive pressure is referred to as a positive fistula test result. The definition actually requires the presence of documentable nystagmus. The reproduction of symptomatology secondary to positive pressure may have diagnostic importance but does not constitute a positive fistula test.

An objective record of fistula testing can be made using the electronystagmogram (ENG) and the impedance bridge. To accomplish this, the emittance probe is placed into first one ear and then the other. The pressure in the external auditory canal is varied between +200 and -200 mm of mercury. The ENG has been examined for induced nystagmus. Each ear is tested separately. A positive fistula result is identified by the production of nystagmus associated with a change in pressure on the tympanic membrane. In some cases, the nystagmus can be seen to change direction as the pressure changes from positive to negative. One would expect that the patient's subjective symptoms of vertigo, with or without nausea, would be induced during the presence of nystagmoid eye movements in a positive test result. The results of the ENG fistula test then can be compared to platform fistula test results.

Dynamic platform posturography

This test can be used to generate a sensitive test for perilymphatic fistula (PLF). In dynamic platform posturography, pressure is applied to the external auditory canal. The increase or decrease in pressure is transmitted to the tympanic membrane middle ear space and, if a fistula is present, to the inner ear. When perilymphatic fistula (PLF) is present, abnormal sway is generated by these pressure changes. Using the acoustic impedance bridge to quantify changes in external auditory canal pressure and the dynamic platform posturography to quantify anterior, posterior, and lateral sway in response to such pressure changes, a sensitive assessment for perilymphatic fistula (PLF) can be developed. Several studies have demonstrated that patients with positive results from platform fistula testing have a high likelihood of having perilymphatic fistula (PLF).

Previous
Next

Diagnostic Procedures

Poe et al performed middle ear endoscopy in 20 patients with suggested perilymphatic fistula (PLF).[16] They failed to demonstrate fistulas in any patient but placed autologous blood patches in 8 patients around the round and oval windows. No change in hearing was noted postoperatively, but 3-4 patients with preoperative vertigo had relief of symptoms, and 2-3 patients with preoperative positive fistula test results had negative test results postoperatively.

The most troublesome difficulty described by Poe was obscured vision of the oval window and round window niche, secondary to mucosal adhesions. The average human ear contains only 0.07 mL (70 mcL) of perilymph; therefore, even relatively rapid leaks are, in absolute terms, quite small. Even with magnification, leaks involving only 5-10% of the perilymph are difficult to see in an operative field because local anesthetics have been injected, irrigating fluids have been used, and a minimal amount of bleeding may be present.

Previous
 
 
Contributor Information and Disclosures
Author

Peter S Roland, MD  Professor, Department of Neurological Surgery, Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, Director of Clinical Center for Auditory, Vestibular and Facial Nerve Disorders, Chief of Pediatric Otology, University of Texas Southwestern Medical Center; Adjunct Professor of Communicative Disorders, University of Texas School of Human Development

Peter S Roland, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American Laryngological Rhinological and Otological Society, American Neurotology Society, American Otological Society, North American Skull Base Society, and Society of University Otolaryngologists-Head and Neck Surgeons

Disclosure: Alcon Labs Honoraria Speaking and teaching; GSK Honoraria Speaking and teaching; Advanced Bionics Honoraria Board membership; Cochlear Corp Honoraria Board membership; Med El Corp travel grants Consulting

Coauthor(s)

William L Meyerhoff, MD, PhD  Former Chair, Former Professor, Department of Otolaryngology, University of Texas Southwestern Medical School

William L Meyerhoff, MD, PhD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American Bronchoesophagological Association, American College of Surgeons, American Laryngological Rhinological and Otological Society, American Medical Association, American Otological Society, Association for Research in Otolaryngology, Southern Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael E Hoffer, MD  Director, Spatial Orientation Center, Department of Otolaryngology, Naval Medical Center of San Diego

Michael E Hoffer, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery

Disclosure: American biloogical group Royalty Other

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gerard J Gianoli, MD  Clinical Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Tulane University School of Medicine; Vice President, The Ear and Balance Institute; Chief Executive Officer, Ponchartrain Surgery Center

Gerard J Gianoli, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Neurotology Society, American Otological Society, Society of University Otolaryngologists-Head and Neck Surgeons, and Triological Society

Disclosure: Vesticon, Inc. None Board membership

Christopher L Slack, MD  Private Practice in Otolaryngology and Facial Plastic Surgery, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders

Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA  Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society

Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation Unrestricted gift Unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo Consulting; Medvoy Ownership interest Management position; Cerescan Imaging Honoraria Consulting; GYRUS ACMI Honoraria Consulting

References
  1. Goodhill V. Ben H. Senturia lecture. Leaking labyrinth lesions, deafness, tinnitus and dizziness. Ann Otol Rhinol Laryngol. Mar-Apr 1981;90(2 Pt 1):99-106. [Medline].

  2. Hardy PA. Influence of spinal puncture and injection on VIIIth nerve function. J Laryngol Otol. May 1988;102(5):452. [Medline].

  3. Robertson D. Cochlear neurons: frequency selectivity altered by perilymph removal. Science. Oct 11 1974;186(4159):153-5. [Medline].

  4. Flint P, Duckert LG, Dobie RA, et al. Chronic perilymphatic fistula: experimental model in the guinea pig. Otolaryngol Head Neck Surg. Oct 1988;99(4):380-8. [Medline].

  5. Böhmer A. Hydrostatic pressure in the inner ear fluid compartments and its effects on inner ear function. Acta Otolaryngol Suppl. 1993;507:3-24. [Medline].

  6. Ackley RS. Electrocochleographic and histopathologic observation of experimental perilymphatic fistulas in guinea pigs. Boulder: University of Colorado; 1984.

  7. Seltzer S, McCabe BF. Perilymph fistula: the Iowa experience. Laryngoscope. Jan 1986;96(1):37-49. [Medline].

  8. Glasscock ME 3rd, Hart MJ, Rosdeutscher JD, et al. Traumatic perilymphatic fistula: how long can symptoms persist? A follow-up report. Am J Otol. Jul 1992;13(4):333-8. [Medline].

  9. Pullen FW 2nd. Perilymphatic fistula induced by barotrauma. Am J Otol. May 1992;13(3):270-2. [Medline].

  10. Klokker M, Vesterhauge S. Perilymphatic fistula in cabin attendants: an incapacitating consequence of flying with common cold. Aviat Space Environ Med. 2005;76(1):66-8. [Medline].

  11. Grundfast KM, Bluestone CD. Sudden or fluctuating hearing loss and vertigo in children due to perilymph fistula. Ann Otol Rhinol Laryngol. Nov-Dec 1978;87(6 Pt 1):761-71. [Medline].

  12. Reilly JS, Kenna MA. Congenital perilymphatic fistula: an overlooked diagnosis?. Am J Otol. Nov 1989;10(6):496-8. [Medline].

  13. Weber PC, Bluestone CD, Perez B. Outcome of hearing and vertigo after surgery for congenital perilymphatic fistula in children. Am J Otolaryngol. 2003;24(3):138-42. [Medline].

  14. Gibson WP. Electrocochleography in the diagnosis of perilymphatic fistula: intraoperative observations and assessment of a new diagnostic office procedure. Am J Otol. Mar 1992;13(2):146-51. [Medline].

  15. Meyerhoff WL, Yellin MW. Summating potential/action potential ratio in perilymph fistula. Otolaryngol Head Neck Surg. Jun 1990;102(6):678-82. [Medline].

  16. Poe DS, Rebeiz EE, Pankratov MM. Evaluation of perilymphatic fistulas by middle ear endoscopy. Am J Otol. Nov 1992;13(6):529-33. [Medline].

  17. Black FO, Pesznecker S, Norton T, et al. Surgical management of perilymphatic fistulas: a Portland experience. Am J Otol. May 1992;13(3):254-62. [Medline].

  18. Rizer FM, House JW. Perilymph fistulas: the House Ear Clinic experience. Otolaryngol Head Neck Surg. Feb 1991;104(2):239-43. [Medline].

  19. Bojrab DI, Bhansali SA. Fluorescein use in the detection of perilymphatic fistula: a study in cats. Otolaryngol Head Neck Surg. Apr 1993;108(4):348-55. [Medline].

  20. Buchman CA, Luxford WM, Hirsch BE, et al. Beta-2 transferrin assay in the identification of perilymph. Am J Otol. Mar 1999;20(2):174-8. [Medline].

  21. Friedland DR, Wackym PA. A critical appraisal of spontaneous perilymphatic fistulas of the inner ear. Am J Otol. Mar 1999;20(2):261-76; discussion 276-9. [Medline].

  22. Meyerhoff WL, Marple BF. Perilymphatic fistula. Otolaryngol Clin North Am. Apr 1994;27(2):411-26. [Medline].

  23. Meyerhoff WL, Pollock KJ. A patient-oriented approach to perilymph fistula. Arch Otolaryngol Head Neck Surg. Nov 1990;116(11):1317-9. [Medline].

  24. Schuknecht HF, Witt RL. Suppressed sneezing as a cause of hearing loss and vertigo. Am J Otolaryngol. Nov-Dec 1985;6(6):468-70. [Medline].

  25. Walsted A, Salomon G, Olsen KS. Low-frequency hearing loss after spinal anesthesia. Perilymphatic hypotonia?. Scand Audiol. 1991;20(4):211-5. [Medline].

  26. Weider DJ. Treatment and management of perilymphatic fistula: a New Hampshire experience. Am J Otol. Mar 1992;13(2):158-66. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.